Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Down 41.5% in July

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw a significant drop in short interest in July. As of July 31st, there was short interest totaling 13,660,000 shares, adropof41.5% from the July 15th total of 23,360,000 shares. Based on an average daily trading volume, of 5,700,000 shares, the short-interest ratio is currently 2.4 days. Approximately6.1% of the company's stock are sold short. Approximately6.1% of the company's stock are sold short. Based on an average daily trading volume, of 5,700,000 shares, the short-interest ratio is currently 2.4 days.

Analyst Ratings Changes

SGMO has been the topic of a number of analyst reports. Wall Street Zen upgraded Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, June 24th. Finally, Barclays cut their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Sangamo Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $4.50.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 21,793 shares in the last quarter. R Squared Ltd purchased a new stake in Sangamo Therapeutics in the 2nd quarter valued at approximately $28,000. Captrust Financial Advisors purchased a new stake in Sangamo Therapeutics in the 4th quarter valued at approximately $30,000. LPL Financial LLC boosted its holdings in Sangamo Therapeutics by 113.5% in the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 16,498 shares in the last quarter. Finally, Cerity Partners LLC boosted its holdings in Sangamo Therapeutics by 439.2% in the 1st quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 44,800 shares in the last quarter. Hedge funds and other institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Price Performance

Shares of SGMO traded up $0.0131 during midday trading on Friday, reaching $0.5863. 5,088,293 shares of the stock were exchanged, compared to its average volume of 6,626,812. The business's 50-day moving average price is $0.52 and its 200 day moving average price is $0.68. Sangamo Therapeutics has a twelve month low of $0.4111 and a twelve month high of $3.1790. The company has a market capitalization of $176.89 million, a price-to-earnings ratio of -2.02 and a beta of 1.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%.The firm had revenue of $18.31 million for the quarter, compared to analyst estimates of $31.68 million. As a group, equities research analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.